دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Long-Term Outcomes After Atrial Switch Operation for Transposition of the Great Arteries
Craig S. Broberg, MD, MCR,a Alexandra C. van Dissel, MD,a,b Jessica Minnier, P HD, c Jamil Aboulhosn, MD, d Robert M. Kauling, MD, e Salil Ginde, MD, f Eric V. Krieger, MD, g Fred Rodriguez III, MD, h Tripti Gupta, MD,i Sangeeta Shah, MD, i Anitha S. John, MD, PH D, j Timothy Cotts, MD,k W. Aaron Kay, MD,l Marissa Kuo, MD,i Cindy Dwight, RN, ND, l Patricia Woods, NP, a Jeremy Nicolarsen, MD,m Berardo Sarubbi, MD,n Flavia Fusco, MD, n Petra Antonova, MD, o Susan Fernandes, LPD, p Jasmine Grewal, MD, q Jonathan Cramer, MD, r Paul Khairy, MD, PH D, s Pastora Gallego, MD, t Clare O’Donnell, MBC HB, u Jane Hannah, RN, u Mikael Dellborg, MD,v Carla P. Rodriguez-Monserrate, MD, w,x Isabelle Vonder Muhll, MD,y Stephen Pylypchuk, MD,y Anthony Magalski, MD,z Frank Han, MD, aa Adam M. Lubert, MD, bb Joseph Kay, MD, cc Elizabeth Yeung, MD,cc Jolien Roos-Hesselink, MD, PHD, e David Baker, MBBS, dd David S. Celermajer, MBBS, P HD, dd Luke J. Burchill, MD, P HD, ee William M. Wilson, MD, ee Joshua Wong, MBBS, ee Shelby Kutty, MD, ff Alexander R. Opotowsky, MD, MMSC
doi : 10.1016/j.jacc.2022.06.020
Volume 80, Issue 10, 6 September 2022, Pages 951-963
For patients with d-loop transposition of the great arteries (d-TGA) with a systemic right ventricle after an atrial switch operation, there is a need to identify risks for end-stage heart failure outcomes.
Late Systemic Right Ventricle Failure: Moving Toward a Real-Time Prediction Tool∗
Tara Karamlou, MD, MS C, a Paul J. Devlin, MD, MS C,b Miza Salim Hammoud, MD
doi : 10.1016/j.jacc.2022.06.021
Volume 80, Issue 10, 6 September 2022, Pages 964-966
Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome
Oscar Westin, MD, a Emil L. Fosbøl, MD, PHD, a Mathew S. Maurer, MD,b Birgitte P. Leicht, MD,c Philip Hasbak, MD, DMS C,d Anne Kærsgaard Mylin, MD, P HD, e Sara Rørvig, MD, f Thomas Hartvig Lindkær, MD, f Helle Hjorth Johannesen, MD,d Finn Gustafsson, MD, PHD, DMSC
doi : 10.1016/j.jacc.2022.06.026
Volume 80, Issue 10, 6 September 2022, Pages 967-977
Bilateral carpal tunnel syndrome (CTS) is a common extracardiac manifestation of amyloidosis and usually predates overt cardiac amyloidosis (CA) by several years. Screening studies on patients undergoing CTS surgery have shown a low yield of CA (2.0%), but high prevalence of amyloid in the carpal ligament. The proportion of patients with amyloid in the carpal ligament who later develop CA is unknown.
Carpal Tunnel Syndrome and Cardiac Amyloidosis: When Are Numb Hands a Window to the Heart?
Martha Grogan, MD,a Angela Dispenzieri, MD
doi : 10.1016/j.jacc.2022.06.025
Volume 80, Issue 10, 6 September 2022, Pages 978-981
Validated Model for Prediction of Adverse Cardiac Outcome in Patients With Fabry Disease
Christopher Orsborne, MBC H B,a,b,c Joshua Bradley, MR ES, a,b Laura J. Bonnett, PH D, d Luke A. Pleva, MSC ,a,b Josephine H. Naish, P HD, a,b David G. Clark, BS C,b Nik Abidin, MBBS, c Peter Woolfson, MD,c Gaetano Nucifora, PHD, b Matthias Schmitt, P HD, a,b Ana Jovanovic, MD,a,c Christopher A. Miller, P HD, a,b,e Anna B. Reid, P HD
doi : 10.1016/j.jacc.2022.06.022
Volume 80, Issue 10, 6 September 2022, Pages 982-994
The cardiac manifestations of Fabry disease are the leading cause of death, but risk stratification remains inadequate. Identifying patients who are at risk of adverse cardiac outcome may facilitate more evidence-based treatment guidance. Contemporary cardiovascular cardiac magnetic resonance biomarkers have become widely adopted, but their prognostic value remains unclear.
A Roadmap to Predict Adverse Outcome in Fabry Disease
Emanuele Monda, MD, a Giuseppe Limongelli, MD, P HD
doi : 10.1016/j.jacc.2022.06.027
Volume 80, Issue 10, 6 September 2022, Pages 995-997
Cathepsin S Levels and Survival Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes
Kimon Stamatelopoulos, MD, a,b, * Matthias Mueller-Hennessen, MD,c,d, * Georgios Georgiopoulos, MD,a,b Pedro Lopez-Ayala, MD,e Marco Sachse, MD, f Nikolaos I. Vlachogiannis, MD,b Kateryna Sopova, MD,g,h Dimitrios Delialis, MD, a Francesca Bonini, PH D, f Raphael Patras, MD, a Giorgia Ciliberti, MSC ,f Mehrshad Vafaie, MD,c Moritz Biener, MD, c Jasper Boeddinghaus, MD,e Thomas Nestelberger, MD, e Luca Koechlin, MD,e Simon Tual-Chalot, P HD, b Ioannis Kanakakis, MD, a Aikaterini Gatsiou, P HD, b Hugo Katus, MD, c,d Ioakim Spyridopoulos, MD, g,h Christian Mueller, MD, e Evangelos Giannitsis, MD, c,d,y Konstantinos Stellos, MD
doi : 10.1016/j.jacc.2022.05.055
Volume 80, Issue 10, 6 September 2022, Pages 998-1010
Patients with non–ST-segment elevation acute coronary syndromes (NSTE-ACS) are at high residual risk for long-term cardiovascular (CV) mortality. Cathepsin S (CTSS) is a lysosomal cysteine protease with elastolytic and collagenolytic activity that has been involved in atherosclerotic plaque rupture.
Novel Biomarkers for Risk Stratification in NSTE-ACS: Is There a Place for Cathepsin S?
Charalambos Antoniades, MD, PH D, Murray D. Polkinghorne, MBC HB, MP HIL
doi : 10.1016/j.jacc.2022.06.023
Volume 80, Issue 10, 6 September 2022, Pages 1011-1013
Ischemic Heart Disease in Young Women: JACC Review Topic of the Week
Margo B. Minissian, P HD, a,b Puja K. Mehta, MD,c Sharonne N. Hayes, MD,d Ki Park, MD, e Janet Wei, MD, a C. Noel Bairey Merz, MD, a Leslie Cho, MD,f Annabelle Santos Volgman, MD,g Islam Y. Elgendy, MD, h Mamas Mamas, MD,i Melinda B. Davis, MD,j Harmony R. Reynolds, MD, k Kelly Epps, MD, l Kathryn Lindley, MD,m Malissa Wood, MD,n Odayme Quesada, MD,a,o Gregory Piazza, MD, p Carl J. Pepine, MD
doi : 10.1016/j.jacc.2022.01.057
Volume 80, Issue 10, 6 September 2022, Pages 1014-1022
Building a Curriculum for the Cardiovascular Implementation Scientist
Ankeet S. Bhatt, MD, MBA, MS C,a,b Simin Lee, MD, MBA, a Muthiah Vaduganathan, MD, MPH
doi : 10.1016/j.jacc.2022.06.028
Volume 80, Issue 10, 6 September 2022, Pages 1023-1027
RESPONSE: Learning to Implement Change in Cardiovascular Care
Geoffrey D. Barnes, MD, MS C
doi : 10.1016/j.jacc.2022.06.036
Volume 80, Issue 10, 6 September 2022, Pages 1026-1027
Slow Ventricular Tachycardia on Amiodarone: An Adverse Complication or an Efficacy Outcome
James A. Reiffel, MD
doi : 10.1016/j.jacc.2022.05.056
Volume 80, Issue 10, 6 September 2022, Page e75
Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardias: Is the Debate Over?
Karim Benali, MD Raphaël P. Martins, MD, PhD Charles Guenancia, MD, PhD Antoine Da Costa, MD, PhD Christian de Chillou, MD, PhD
doi : 10.1016/j.jacc.2022.05.057
Volume 80, Issue 10, 6 September 2022, Page e77
Reply: Survive the Threat of Slow VT
�ngel Arenal, MD, PhD Pablo �vila, MD
doi : 10.1016/j.jacc.2022.06.024
Volume 80, Issue 10, 6 September 2022, Pages e79-e80
